journal article·2021-07-01

High throughput microfluidic system with multiple oxygen levels for the study of hypoxia in tumor spheroids

Ilana Berger Fridman, Giovanni Stefano Ugolini, Virginia VanDelinder, Smadar Cohen, Tania Konry

Biofabrication· Volume 13· Issue 3
Publisher page

Abstract

Abstract Replication of physiological oxygen levels is fundamental for modeling human physiology and pathology in in vitro models. Environmental oxygen levels, applied in most in vitro models, poorly imitate the oxygen conditions cells experience in vivo , where oxygen levels average ∼5%. Most solid tumors exhibit regions of hypoxic levels, promoting tumor progression and resistance to therapy. Though this phenomenon offers a specific target for cancer therapy, appropriate in vitro platforms are still lacking. Microfluidic models offer advanced spatio-temporal control of physico-chemical parameters. However, most of the systems described to date control a single oxygen level per chip, thus offering limited experimental throughput. Here, we developed a multi-layer microfluidic device coupling the high throughput generation of 3D tumor spheroids with a linear gradient of five oxygen levels, thus enabling multiple conditions and hundreds of replicates on a single chip. We showed how the applied oxygen gradient affects the generation of reactive oxygen species (ROS) and the cytotoxicity of Doxorubicin and Tirapazamine in breast tumor spheroids. Our results aligned with previous reports of increased ROS production under hypoxia and provide new insights on drug cytotoxicity levels that are closer to previously reported in vivo findings, demonstrating the predictive potential of our system.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer, Hypoxia, and Metabolism · Innovative Microfluidic and Catalytic Techniques Innovation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (77)

Show source-provided references
1. Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis10.1634/theoncologist.13-S3-21 ↗
2. Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response10.1259/bjr.20130676 ↗
3. Detection and characterization of tumor hypoxia using pO2 histography10.1089/ars.2007.1628 ↗
4. The hypoxic tumor microenvironment: A driving force for breast cancer progression10.1016/j.bbamcr.2015.05.036 ↗
5. Hypoxia and oxidative stress in breast cancer Hypoxia and tumourigenesis10.1186/bcr314 ↗
6. Hypoxia promotes breast cancer cell invasion through HIF-1α-mediated up-regulation of the invadopodial actin bundling protein CSRP210.1038/s41598-018-28637-x ↗
7. Hypoxic control of metastasis10.1126/science.aaf4405 ↗
8. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours10.1038/379088a0 ↗
9. The role of tumor-associated macrophages in breast cancer progression10.3892/ijo.2013.1938 ↗
10. Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin10.18632/oncotarget.2110 ↗
11. Cytokine regulation of angiogenesis in breast cancer: the role of tumor‐associated macrophages10.1002/jlb.57.5.747 ↗
12. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
13. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome10.1007/s10549-010-1154-y ↗
14. Exploiting tumour hypoxia in cancer treatment10.1038/nrc1367 ↗
15. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
16. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells10.1016/S0021-9258(19)61441-9 ↗
17. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism of O2 sensing10.1074/jbc.M001914200 ↗
18. Reactive oxygen species in tumor progression10.2741/1667 ↗
19. Microenvironment-induced cancer metastasis10.1080/095530000138259 ↗
20. Roles of oxidative stress in the development and progression of breast cancer10.7314/APJCP.2014.15.12.4745 ↗
21. Reactive oxygen species in cancer10.3109/10715761003667554 ↗
22. Hypoxia: a double-edged sword in cancer therapy10.1080/07357907.2016.1245317 ↗
23. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs10.1007/s00280-015-2920-7 ↗
24. Frequently asked questions in hypoxia research10.2147/HP.S92198 ↗
25. CoCl2, a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer10.1371/journal.pone.0099143 ↗
26. The hypoxia-mimetic agent CoCl2 induces chemotherapy resistance in LOVO colorectal cancer cells10.3892/mmr.2016.4836 ↗
27. Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1α independent mechanisms10.1007/s10495-005-3085-3 ↗
28. Human cardiac fibroblasts adaptive responses to controlled combined mechanical strain and oxygen changes in vitro10.7554/eLife.22847 ↗
29. 3D liver models on a microplatform: well-defined culture, engineering of liver tissue and liver-on-a-chip10.1039/C5LC00611B ↗
30. Lung-on-a-chip: the future of respiratory disease models and pharmacological studies10.1080/07388551.2019.1710458 ↗
31. Modelling cancer in microfluidic human organs-on-chips10.1038/s41568-018-0104-6 ↗
32. Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform10.1039/C5LC01139F ↗
33. A Simple Vacuum‐Based Microfluidic Technique to Establish High‐Throughput Organs‐On‐Chip and 3D Cell Cultures at the Microscale10.1002/admt.201800319 ↗
34. A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment10.1039/c2lc40306d ↗
35. Oxygen control with microfluidics10.1039/C4LC00853G ↗
36. Designing a microfluidic device with integrated ratiometric oxygen sensors for the long-term control and monitoring of chronic and cyclic hypoxia10.3390/s150820030 ↗
37. Culturing aerobic and anaerobic bacteria and mammalian cells a microfluidic differential oxygenator10.1021/ac9006864 ↗
38. Alginate: Properties and biomedical applications10.1016/j.progpolymsci.2011.06.003 ↗
39. Hepatocyte behavior within three‐dimensional porous alginate scaffolds10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2 ↗
40. Novel alginate sponges for cell culture and transplantation10.1016/S0142-9612(96)00181-0 ↗
41. Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium?10.1161/01.CIR.102.suppl_3.III-56 ↗
42. Bioengineering 3D environments for cancer models10.1016/j.addr.2014.06.004 ↗
43. Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death10.1158/0008-5472.CAN-05-3410 ↗
44. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins10.1186/s12885-017-3953-6 ↗
45. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1alpha10.1158/1535-7163.MCT-13-0490 ↗
46. Optical oxygen sensing properties of Ru(II) complex and porous silica nanoparticles embedded in solgel matrix10.1364/AO.50.00E145 ↗
47. Optical methods for sensing and imaging oxygen: materials, spectroscopies and applications10.1039/C4CS00039K ↗
48. Optical imaging in microfluidic bioreactors enables oxygen monitoring for continuous cell culture10.1117/1.2355665 ↗
49. In vivo phosphorescence imaging of cancer using iridium complexes10.1117/12.814494 ↗
50. A microfluidic oxygen sink to create a targeted cellular hypoxic microenvironment under ambient atmospheric conditions10.1016/j.actbio.2018.04.007 ↗
51. Engineering oxygen nanobubbles for the effective reversal of hypoxia10.1080/21691401.2018.1492420 ↗
52. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression10.1155/2016/3907147 ↗
53. Hypoxia and oxidative stress in breast cancer Oxidative stress - its effects on the growth, metastatic potential and response to therapy of breast cancer10.1186/bcr315 ↗
54. Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype10.15252/embj.201695204 ↗
55. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription10.1073/pnas.95.20.11715 ↗
56. ROS signalling in the biology of cancer10.1016/j.semcdb.2017.05.023 ↗
57. The FGF/FGF receptor axis as a therapeutic target in breast cancer10.1155/2016/4549676 ↗
58. ROS homeostasis and metabolism: a critical liaison for cancer therapy10.1038/emm.2016.119 ↗
59. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages10.1038/cr.2013.75 ↗
60. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation10.1016/j.cmet.2005.05.003 ↗
61. O2 sensing, mitochondria and ROS signaling: the fog is lifting10.1016/j.mam.2016.01.002 ↗
62. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner10.1016/j.canlet.2008.02.012 ↗
63. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment10.1158/0008-5472.CAN-04-3395 ↗
64. Why do cancers have high aerobic glycolysis?10.1038/nrc1478 ↗
65. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene10.1007/s00280-006-0224-7 ↗
66. Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia10.1038/s41598-019-54001-8 ↗
67. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems10.1111/j.2042-7158.2012.01567.x ↗
68. Safety and efficacy of tirapazamine as anti-cancer drug: a meta-analysis of randomized controlled trials10.18203/2319-2003.ijbcp20181187 ↗
69. Tirapazamine: from bench to clinical trials10.2174/157488406775268192 ↗
70. Cellular and molecular mechanisms in the hypoxic tissue: role of HIF-1 and ROS10.1002/cbf.2985 ↗
71. Celeste Simon · 2007 · 588
72. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast10.1186/1471-2407-12-4 ↗
73. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice10.1006/taap.1999.8834 ↗
74. Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release10.1016/j.jconrel.2018.12.010 ↗
75. Generation of complex concentration profiles in microchannels in a logarithmically small number of steps10.1039/B610011B ↗
76. Fine temporal control of the medium gas content and acidity and on-chip generation of series of oxygen concentrations for cell culture10.1039/b816191g ↗
77. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide10.1186/s12885-015-1546-9 ↗